SCHEMBL20535813

SCHEMBL20535813

COC(=O)c1ccc2c3cc(-n4ccnc4)ccc3n(CCC(N)=O)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.53
MAPT P10636 4/20 0.40
DYRK1A Q13627 1/20 0.40
CYP3A4 P08684 1/20 0.40
BAZ2B Q9UIF8 1/20 0.40
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
SCARB1 Q8WTV0 1/20 0.38
ADH5 P11766 2/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
F10 P00742 1/20 0.37
MAPK8 P45983 1/20 0.36
MAPK10 P53779 1/20 0.36
PTGER4 P35408 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CNR2 P34972 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30772952 1.00 HTT (0.53) HTTMAPTDYRK1ACYP3A4BAZ2B
SCHEMBL25492135 0.89 CYP3A4 (0.50) HTTMAPTDYRK1ACYP3A4BAZ2B
SCHEMBL20536337 0.88 ADH5 (0.46) HTTMAPTCYP3A4BAZ2BKDM4E
SCHEMBL30772967 0.88 ADH5 (0.46) HTTMAPTCYP3A4BAZ2BKDM4E
SCHEMBL22077041 0.84 ADH5 (0.46) HTTMAPTCYP3A4BAZ2BKDM4E
SCHEMBL20536593 0.83 ADH5 (0.49) HTTMAPTCYP3A4BAZ2BKDM4E
SCHEMBL30772970 0.83 ADH5 (0.49) HTTMAPTCYP3A4BAZ2BKDM4E
SCHEMBL22077998 0.83 ADH5 (0.49) HTTMAPTCYP3A4BAZ2BKDM4E
SCHEMBL25492140 0.81 TBXAS1 (0.40) MAPTDYRK1ACYP3A4BAZ2BLMNA
SCHEMBL22077999 0.80 DYRK1A (0.46) HTTMAPTDYRK1ACYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3609867-B1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSNO THERAPEUTICS INC (US) 2024-05-15 EP disclosed
CN-110753683-B Carbazole compounds and methods of use thereof 吉斯诺治疗公司 2024-02-09 CN disclosed
US-11655244-B2 Carbazole compounds and methods of use thereof GSNO THERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-11655244-B2 Carbazole compounds and methods of use thereof GSNO THERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-11655244-B2 Carbazole compounds and methods of use thereof GSNO THERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSNO THERAPEUTICS, INC. 2020-06-11 US disclosed
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSNO THERAPEUTICS, INC. 2020-06-11 US disclosed
EP-3609867-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF Saje Pharma, LLC (US) 2020-02-19 EP disclosed
CN-110753683-A Carbazole compounds and methods of use thereof 赛吉制药有限责任公司 2020-02-04 CN disclosed
WO-2018191418-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF SAJE PHARMA, LLC (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655244-B2 Carbazole compounds and methods of use thereof GSR, CBR3, CBR1 HTT 2753/4885MAPT 4280/4885DYRK1A 3058/4885
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSR, CBR3, CBR1 HTT 2753/4885MAPT 4280/4885DYRK1A 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.